AstraZeneca, Samsung Biologics Form $331-M Mfg Partnership

By Miranda Greenberg -

September 24, 2020

AstraZeneca and Samsung Biologics, an Incheon, South Korea-based contract biologics manufacturer, have entered into a long-term supply agreement, valued at approximately $330.8 million, to support AstraZeneca’s biologics therapeutics.

Under the agreement, Samsung Biologics will provide large-scale commercial manufacturing for drug substances and dug products of AstraZeneca’s biologics. The value of the agreement could be increased to $545.6 million.

The companies had signed a letter of intent in June (June 2020).

Source: Samsung Biologics